Anna M. Scattolin

Venice, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Journal: Cancer
Published: May 06, 2025

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Journal: American journal of hematology
Published: March 28, 2025

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.

Journal: Blood advances
Published: December 21, 2022

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.

Journal: British journal of haematology
Published: August 08, 2022

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report.

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report.

Journal: Haematologica
Published: November 18, 2021

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Journal: Haematologica
Published: September 06, 2021

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.

Journal: Blood cancer journal
Published: August 19, 2020

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.

Journal: The Lancet. Haematology
Published: June 09, 2020

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Journal: Blood cancer journal
Published: May 23, 2020

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06.

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06.

Journal: Haematologica
Published: March 22, 2020

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.

Journal: Leukemia & lymphoma
Published: July 13, 2019

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Journal: Blood advances
Published: May 07, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026